Insider Transactions in Q1 2025 at New Amsterdam Pharma CO N.V. (NAMS)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 30
2025
|
Douglas F Kling Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
13,578
-12.47%
|
-
|
|
Jan 30
2025
|
Douglas F Kling Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,578
+19.08%
|
-
|
|
Jan 29
2025
|
Douglas F Kling Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
56,863
-56.38%
|
-
|
|
Jan 29
2025
|
Douglas F Kling Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
56,863
+36.05%
|
-
|
|
Jan 28
2025
|
Mayur Ian Somaiya Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
14,900
-14.98%
|
-
|
|
Jan 28
2025
|
Mayur Ian Somaiya Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,900
+21.98%
|
$134,100
$9.26 P/Share
|
|
Jan 28
2025
|
Douglas F Kling Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
25,385
-19.82%
|
-
|
|
Jan 28
2025
|
Douglas F Kling Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,385
+26.79%
|
-
|
|
Jan 27
2025
|
Mayur Ian Somaiya Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
46,983
-32.78%
|
-
|
|
Jan 27
2025
|
Mayur Ian Somaiya Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
46,983
+35.6%
|
$422,847
$9.26 P/Share
|
|
Jan 27
2025
|
Douglas F Kling Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
104,174
-44.68%
|
-
|
|
Jan 27
2025
|
Douglas F Kling Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
104,174
+41.28%
|
-
|
|
Jan 07
2025
|
Mark C. Mc Kenna |
BUY
Grant, award, or other acquisition
|
Direct |
6,960
+50.0%
|
-
|
|
Jan 07
2025
|
John W Smither |
BUY
Grant, award, or other acquisition
|
Direct |
6,960
+50.0%
|
-
|
|
Jan 07
2025
|
William Lewis |
BUY
Grant, award, or other acquisition
|
Direct |
6,960
+50.0%
|
-
|
|
Jan 07
2025
|
Louis G Lange |
BUY
Grant, award, or other acquisition
|
Direct |
6,960
+50.0%
|
-
|
|
Jan 07
2025
|
Kamp Hilde Johanna Van Der |
BUY
Grant, award, or other acquisition
|
Direct |
6,960
+50.0%
|
-
|
|
Jan 07
2025
|
Johannes Jacob Pieter Kastelein Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,000
+50.0%
|
-
|
|
Jan 07
2025
|
Michael H. Davidson Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
123,529
+50.0%
|
-
|
|
Jan 07
2025
|
Louise Frederika Kooij Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+50.0%
|
-
|
|
Jan 07
2025
|
Juliette Berangere Audet Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+48.1%
|
-
|
|
Jan 07
2025
|
Douglas F Kling Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
44,000
+50.0%
|
-
|
|
Jan 07
2025
|
William A Jones Jr Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,000
+50.0%
|
-
|
|
Jan 07
2025
|
Mayur Ian Somaiya Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
38,000
+50.0%
|
-
|